Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reply to 'Comment on "Toxicities in long-term survivors of head and neck cancer-A multi-national cross-sectional analysis"'.

International journal of cancer·2025

Same author

Unmet supportive care needs among head and neck cancer survivors beyond 5 years after diagnosis: a multinational cohort study.

The Lancet regional health. Europe·2025

Same author

Toxicities in long-term survivors of head and neck cancer-A multi-national cross-sectional analysis.

International journal of cancer·2025

Same author

Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.

Journal of hematology & oncology·2025

Same author

WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.

Journal of hematology & oncology·2025

Same author

Long-term health-related quality of life in head and neck cancer survivors: A large multinational study.

International journal of cancer·2024

Search research articles

Related Experiment Video

Updated: Mar 18, 2026

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Ipilimumab in melanoma.

Pol Specenier¹

¹a Oncology , Universitair Ziekenhuis Antwerpen , Edegem , Belgium.

Expert Review of Anticancer Therapy

|July 13, 2016

Summary

Melanoma treatment advances include targeted therapies and immunotherapies like checkpoint inhibitors. While ipilimumab was an early immunotherapy, newer agents like pembrolizumab and nivolumab show superior efficacy, with combination therapy offering potential benefits but increased toxicity.

Area of Science:

Oncology
Dermatology
Immunotherapy

Background:

Melanoma treatment has rapidly evolved, with targeted therapies for BRAF mutations and immunotherapies for various tumor types.
Checkpoint inhibitors represent a significant advancement in melanoma treatment.

Purpose of the Study:

To review the efficacy, safety, and pharmacoeconomics of ipilimumab in melanoma treatment.
To compare ipilimumab with newer anti-PD1 therapies and combination strategies.

Main Methods:

Comprehensive literature review on ipilimumab and other checkpoint inhibitors in melanoma.
Analysis of efficacy, predictive markers, safety, and pharmacoeconomic data.

Main Results:

Ipilimumab was the first checkpoint inhibitor approved for metastatic melanoma but is now surpassed by anti-PD1 antibodies (pembrolizumab, nivolumab).

Keywords:

Ipilimumab adjuvant advanced melanoma metastatic

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

Related Experiment Videos

Last Updated: Mar 18, 2026

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

Combination of ipilimumab with nivolumab improves response rates and progression-free survival (PFS), especially in PD-L1 negative tumors, but increases severe adverse events.

Data on definitive survival and pharmacoeconomic implications of combination therapy are pending.

Conclusions:

Anti-PD1 antibodies are now the standard first-line treatment for metastatic melanoma.
Combination ipilimumab and nivolumab shows promise but requires further investigation regarding long-term survival, patient selection, and cost-effectiveness.